Study registration: *
Publication Glatman-Freedman A, Emerg Infect Dis, 2021
Dates: 2021-07-01 to 2021-07-24
Funding: Not reported/unclear
Conflict of interest: no COI (Dr. Glatman-Freedman is the director of the Infectious Diseases Unit in the Israel Center for Disease Control. She is affiliated academically with the School of Public Health at Tel Aviv University. Her primary research interests are the epidemiology of respiratory viruses, syndromic surveillance, and vaccine effectiveness.)

Methods

Study design:Cohort
Description of participants: Adolescents 12–15 years of age with no history of COVID-19 in Israel
Inclusion criteria:
  • Adolescent Israel residents 12–15 years of age who had received the second vaccine dose during July 1–24, 2021
  • Unvaccinated controls for each date during July 1–24, 2021 were determined by omitting the number of fully vaccinated adolescent Israel residents 12–15 years of age who had received the second BNT162b2 vaccine dose on a particular date from the total number of Israel residents who did not have a documented SARS-CoV-2–positive test result and had not received only a single vaccine dose by that date

Exclusion criteria:
  • Adolescents who had had a documented SARS-CoV-2–positive PCR result before the evaluation periods, regardless of their vaccination status

Follow-up duration (months): 1.7
Vaccines:
  • 2 doses of BNT162b2
Variant description :
Variant name: Delta
Evidence: Indirect evidence (prevalence of variant in the population: 93–99%)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: NR
Data accessibility: NR
General comment Concerns about uncontrolled confounding, exclusion of single-vaccinated individuals and absence of a pre-determined analysis plan.